拉帕替尼合成工艺的研究进展

doi:10.16085/j.issn.1000-6613.2017.03.034

摘要/Abstract

摘要：

拉帕替尼（Lapatinib）是一种口服的新型小分子表皮生长因子酪氨酸激酶抑制剂（TKIs），临床治疗Ⅱ型人表皮生长因子受体过度表达引起的晚期或转移性乳腺癌。本文回顾了近十年以来有关拉帕替尼生产及应用的文献及专利，介绍了拉帕替尼的主要工艺合成路线，系统阐述其3种关键中间体（包括3-氯-4-（3-氟苄氧基）苯胺（2）、N-（3-氯-4-（3-氟苄氧基）苯基）-6-碘喹唑啉-4-胺（3）和5-[4-[3-氯-4-[（3-氟苄氧基）苯基]氨基]-6-喹唑啉]-2-呋喃甲醛（4））和两种关键原料（苯并嘧啶和2-甲砜基乙胺盐酸盐）的合成工艺，研究了各种路线之间的异同与特点，比较各条路线的优劣，指出了各种关键中间体、原料和终产物拉帕替尼的最优合成工艺。

关键词: 拉帕替尼, 酪氨酸激酶抑制剂, 生产, 合成, 化学反应

Abstract:

Lapatinib,a new kind of epidermal growth factor tyrosine kinase inhibitors of small molecules,is employed for clinical therapy of the advanced or metastatic breast cancer induced by the overexpression of human epidermal growth factor receptor-Ⅱ. This paper reviews the relevant literatures and patents about the production and application of Lapatinib in the last ten years,mainly introduces the synthetic process of Lapatinib and expounds systematically the synthetic process of its three key intermediates (3-chloro-4-(3-fluorobenzyloxy)aniline,N-[3-chloro-4-(3-fluorobenzyloxy) phenyl]-6-iodoquinazolin-4-amine and 5-(4-((3-chloro-4-((3-fluorobenzyl)oxy) phenyl)amino) quinazolin-6-yl)furan-2-carbaldehyde) and two key raw materials (quinazoline and 2-aminoethylmethylsulfonehydrochloride). The differences and features of various routes and the advantages and disadvantages of various routes are discussed. Optimal synthestic technology of the key intermediates raw materials and the final products-Lapatinib is presented.

Key words: Lapatinib, tyrosine kinase inhibitor, production, synthesis, chemical reaction

中图分类号:

TQ463⁺.4

赵心瑜, 徐明超, 郭庆美, 李晓梅, 滕明瑜. 拉帕替尼合成工艺的研究进展[J]. 化工进展, 2017, 36(03): 1018-1032.

ZHAO Xinyu, XU Mingchao, GUO Qingmei, LI Xiaomei, TENG Mingyu. Research progress on the synthetic technology of Lapatinib[J]. Chemical Industry and Engineering Progress, 2017, 36(03): 1018-1032.

参考文献

[1] GAO H,WANG Y,CHEN C,et al. Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug[J]. Int. J. Pharm.,2014,461:478-488.
[2] HIGA G,ABRAHAM J. Lapatinib in the treatment of breast cancer[J]. Expert Rev. Anticancer Ther.,2007,7(9):1183-1192.
[3] 于丁,廖宁. 拉帕替尼联合卡培他滨治疗HER2过表达晚期乳腺癌的疗效评价[J]. 循证医学,2008,8(3):140-142. YU D,LIAO N. The therapeutic effect evaluation of lapatinib plus capecitabine for HER2 positive advanced breast cancer[J]. J. Evid.-Based Med.,2008,8(3):140-142.
[4] GNIAZDOWSKA E,KOZMINSKI P,BANKOWSKI K,et al. Synthesis,physicochemical and biological evaluation of technetium-99m labeled lapatinib as a novel potential tumor imaging agent of Her-2 positive breast cancer[J]. Eur. J. Med. Chem.,2014,87:493-499.
[5] LYU A,FANG L,GOU S. Design and synthesis of lapatinib derivatives containing a branched side chain as HER1/HER2 targeting anti-tumor drug candidates[J]. Eur. J. Med. Chem.,2014, 87:631-642.
[6] FRANKLIN M,CAREY K,VAJDOS F,et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex[J]. Cancer Cell,2004,5:317-328.
[7] PATRICK J,GOODIN S. Lapatinib:a dual inhibitor of human epidermal growth factor receptor tyrosine kinases[J]. Clin. Ther., 2008,30(8):1426-1447.
[8] WALLACE E,TOPOLOV G,ZHAO Q,et al. Cyanoguanidines and cyanoamidines as ERBB2/EGFR inhibitors:US20050101617A1[P]. 2005-05-12.
[9] CHEW W,CHEAL G,LUNETTA J. Preparation methods of substituted 3-cyanoquinolines and their intermediates:WO2006127207[P]. 2006-11-30.
[10] TANG P,FENG J,FENG F, et al. Preparation methods of quinazoline derivatives and their pharmaceutical uses:WO2009012647A1[P]. 2009-01-29.
[11] ZHANG C,DUMAS J,ZHU Q,et al. Novel heterocycles:WO2006023843A2[P]. 2006-03-02.
[12] RAHEEM M,WEERATUNGA G,ZETINA-ROCHA C,et al. Process for the preparation of lapatinib and its ditosylate salt:US8952154B2[P]. 2011-12-23.
[13] LIU L, YUAN T, LIU H, et al. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivativesas potent EGFR inhibitors[J]. Bioorg. Med. Chem. Lett., 2007:6373-6377.
[14] 任晓岚,汪鑫,李志裕,等. 表皮生长因子受体(EGFR)酪氨酸激酶抑制剂的研究进展[J]. 中国新药杂志,2005,14(7):821-826. REN X L,WANG X,LI Z Y,et al. Research progresses of epidermal growth factor receptor tyrosine kinase inhibitors[J]. Chin. J. New Drugs,2005,14(7):821-826.
[15] EDWARD H, WEN C, CHEN P, et al. δ-Substituted pyrrolotriazine compounds:WO2005/065266[P]. 2005-07-21.
[16] ZHANG X,RAGHAVAN S,IHNAT M,et al. The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d] pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents[J]. Bioorg. Med. Chem.,2015,23:2408-2423.
[17] NIE W, SONG W,ZHANG W, et al. miR-1470 mediates lapatinib induced p27 upregulation by targeting c-jun[J]. J. Cell. Physiol.,2015,230(7):1630-1639.
[18] 李连连,张庆文. 3-氯-4-(3-氟苄氧基)苯胺的合成[J]. 中国现代应用药学,2011,28(3):245-246. LI L L, ZHANG Q W. Practical synthesis of 3-chloro-4-(3-fluorobenzyloxy)aniline[J]. Chin. J. Mod. Appl. Pharm.,2011,28(3):245-246.
[19] FRANCESCO F,ALFREDO P. Efficient process for the preparation of lapatinib and salts thereof by means of new intermediates:US9024023B2[P]. 2013-09-03.
[20] 王武伟,江珂,李飞,等. N-(3-氯-4-(3-氟苯甲氧基)苯基)-6-碘喹唑啉-4-胺盐酸盐的合成[J]. 化工中间体,2008,11:28-30. WANG W W, JIANG K, LI F, et al. Synthesis of N-(3-chloro-4-((3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine hydrochloride[J]. Chem. Intermed.,2008,11:28-30.
[21] 蔡志强,石玉,袁静,等. N-{3-氯-4-[(3-氟苄基)氧基]苯基}-6-碘喹唑啉-4-胺的合成工艺改进[J]. 合成化学,2011,19(3):421-424. CAI Z Q,SHI Y,YUAN J,et al. Process improvement on the synthesis of N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-iodoquinazolin-4-amine[J]. Chin. J. Synth. Chem.,2011,19(3):421-424.
[22] 袁建勇,郭卿,李雁武. 一种制备拉帕替尼的方法和中间体:201510593037. 4[P]. 2015-09-12. YUAN J Y,GUO Q,LI Y W. Method for preparing lapatinib and intermediate:201510593037. 4[P]. 2015-09-12.
[23] 汪志勇,万常峰,王晔. 拉帕替尼中间体及其类似物的制备方法:201110189054.3[P]. 2011-07-07. WANG Z Y,WAN C F,WANG Y. Preparation method of lapatinib intermediate and analogues thereof:201110189054.3[P]. 2011-07-07.
[24] 李飞,王武伟,季兴,等. 拉帕替尼合成中间体的制备工艺:200910033327.8[P]. 2009-06-18. LI F,WANG W W,JI X,et al. Process for preparing lapatinib synthetic intermediate:200910033327.8[P]. 2009-06-18.
[25] JYOTHI P,ADINHATLA K,VENKAIAH C. Novel process for the preparation of lapatinib and its pharmaceutically acceptable salts:US20110263852[P]. 2011-10-27.
[26] 贾玉才,卢俊金,郑彦军,等. 拉帕替尼中间体N-[3-氯-4-(3-氟苄氧基)苯氨基]-6-碘喹唑啉的合成新方法[J]. 陕西师范大学学报(自然科学版),2013,41(6):42-45. JIA Y C,LU J J,ZHENG Y J,et al. A new method for synthesis of N-[3-chloro-4-(3-fluorophenzyloxy)phenyl]-6-iodoquinazolin-4-amine[J]. J.Shaanxi Norm. Univ. (Nat. Sci. Ed.),2013,41(6):42-45.
[27] ELKAMHAWY A,FARAG A,VISWANATH A,et al. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted-4-anilinoquinazoline hybrids:Design, synthesis, kinase assay,cell-based assay,and molecular docking[J]. Bioorg. Med. Chem. Lett.,2015,25:5147-5154.
[28] MCCLURE M S,ROSCHANGAR F,HODSON S J,et al. A practical one-pot synthesis of 5-aryl-2-furaldehydes[J]. Synthesis, 2001(11):1681-1685.
[29] ISMAIL R,ISMAIL N,ABUSERII S,et al. Recent advances in 4-aminoquinazoline based scaffold derivatives targeting EGFR kinases as anticancer agents[J]. Future J. Pharm. Sci.,2016,8:337-339.
[30] LACKEY K,SPECTOR N,WOOD E,et al. Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent:WO02056912[P]. 2002-07-25.
[31] ESTOK T,ZAKNOEN S,MANSFIELD R,et al. Combination the rapy for the treatment of cancer using COX-2 inhibitors and dual inhibitors of EGFR (ErbB1) and HER2(Erb-B2):WO2009042613[P]. 2009-04-02.
[32] CARTER M,COCKERILL G,GUNTRIP S, et al. Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors:US6727256[P]. 2004-04-27.
[33] ERICKSON G,GUO J,MCCLURE M, et al. Synthesis of lapatinib via direct regioselective arylation of furfural[J]. Tetrahedron Lett.,2014,55:6007-6010.
[34] KANO H,LIDA Y. Process for preparing 2-(methylsulfonyl)-ethylamine:JP2002020365[P]. 2002-01-23.
[35] PETROV K,ZHANG Y,CARTER M,et al. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series[J]. Bioorg. Med. Chem. Lett.,2006,16:4686-4691.
[36] HWANG C,TARLTON E,PISCOPIO A. Process for the reduction of cyano-substituted sulfones to aminoalkylene-substituted Sulfones:WO2001083432[P]. 2001-11-08.
[37] 王武伟. 拉帕替尼及其中间体的合成研究[D]. 南京:南京医科大学,2009. WANG W W. Study on the synthesis of lapatinib and its intermediates[D]. Nanjing:Nanjing Medical University,2009.
[38] 张立鹏,齐英超,李斌,等. 一种拉帕替尼中间体的制备方法:201210534897[P]. 2013-04-10. ZHANG L P,QI Y C,LI B,et al. Preparation method of lapatinib intermediate:201210534897[P]. 2013-04-10.
[39] ABRAHAM S,BHAGWAT S,CAMPBELL B,et al. Quinazoline derivatives as raf-kinae modulators and methods of use thereof:WO2009117080[P]. 2010-11-04.
[40] TUNG R. 4-Aminoquinazoline derivatives and methods of use thereof:WO2008024439[P]. 2008-02-28.
[41] TUNG R,Morgan A. 4-Aminoquinazoline derivatives and methods of use thereof:US2011053964[P]. 2011-03-03.
[42] MCCLURE M,OSTERHOUT M,ROSCHANGAR F, et al. Quinazoline ditosylate salt compounds:WO2002002552A1[P]. 2002-01-10.
[43] 季兴,王武伟,许贯虹,等. 拉帕替尼的合成[J]. 中国医药工业杂志,2009,40(11):801-804. JI X,WANG W W,XU G H,et al. Synthesis of lapatinib[J]. Chin. J. Pharmaceut.,2009,40(11):801-804.
[44] 张庆文,周后元,尤启冬. 拉帕替尼合成工艺研究[J]. 中国药科大学学报,2010,41(4):317-320. ZHANG Q W,ZHOU H Y,YOU Q D. Practical synthesis of lapatinib[J]. J. Chin. Pharmaceut. Univ.,2010,41(4):317-320.
[45] JYOTHI P,ADIBHATLA K,VENKAIAH C. A novel process for the preparation of lapatinib and its pharmaceutically acceptable salts:WO2010061400[P]. 2010-06-03.
[46] 周艳红,袁哲东,王胡博,等. 一种制备拉帕替尼的方法:104109152[P]. 2014-10-22. ZHOU Y H,YUAN Z D,WANG H B,et al. Method for preparing lapatinib:104109152[P]. 2014-10-22.
[47] CHEN Y,HENSCHKE J,LIU Y,et al. Process and intermediates for preparing lapatinib:WO2011116634[P]. 2011-09-29.
[48] 王晶翼, 林栋, 冷传新, 等. 拉帕替尼的制备方法:102295638B[P]. 2010-06-24. WANG J Y,LIN D,LENG C X,et al. Novel method for preparing lapatinib:102295638B[P]. 2010-06-24.
[49] 庄韦,岳邦毅,陈强. 一种二对甲苯磺酸拉帕替尼的合成方法:103159747 A[P]. 2013-06-19. ZHUANG W, YUE B Y, CHEN Q. Synthetic method of lapatinib:103159747 A[P]. 2013-06-19.